+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

From
From
Bispecific Antibodies - Global Strategic Business Report - Product Thumbnail Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • August 2025
  • 104 Pages
  • Global
From
From
From
MEK Inhibitors - Global Strategic Business Report - Product Thumbnail Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • August 2025
  • 132 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • August 2025
  • 224 Pages
  • Global
From
Combination Antibody Therapy - Global Strategic Business Report - Product Thumbnail Image

Combination Antibody Therapy - Global Strategic Business Report

  • Report
  • August 2025
  • 196 Pages
  • Global
From
Gynecological Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 193 Pages
  • Global
From
Urothelial Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Urothelial Cancer Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 126 Pages
  • Global
From
From
Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 193 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • August 2025
  • 277 Pages
  • Global
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Thumbnail Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 280 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025 - Product Thumbnail Image

PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025

  • Report
  • April 2025
  • 400 Pages
  • Global
From
IPSC Derived NK Cells- Pipeline Insight, 2025 - Product Thumbnail Image

IPSC Derived NK Cells- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Papillary Thyroid Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Papillary Thyroid Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more